Table 3.

Multivariable predictors of relapse in the GDCN and French ANCA vasculitis cohorts^*

	GDCN cohort (n = 255)		French cohort (n = 359)
	HR (95% CI)	P	HR (95% CI)	P
PR3 ANCA vs. MPO ANCA antibody status	1.77 (1.11–2.82)	0.017†	1.66 (1.15–2.39)	0.006†
Lung involvement	1.68 (1.10–2.57)	0.017†	1.56 (1.11–2.20)	0.010†
Upper respiratory tract involvement	1.58 (1.00–2.48)	0.048†	0.96 (0.67–1.38)	0.820†
Lung involvement and PR3 ANCA vs. MPO ANCA antibody status	2.46 (1.60–3.77)	<0.0001‡	1.57 (1.13–2.18)	0.007‡

^*Hazard ratios (HRs) and 95% CIs were estimated using proportional hazards models. The group of patients with PR3 ANCA included those with PR3 and/or cytoplasmic ANCA; the group of patients with MPO ANCA included those with MPO and/or perinuclear ANCA. See Table 2 for other definitions.

^†Controlled for age, sex, race, serum creatinine level, therapy (immunosuppressants plus corticosteroids versus corticosteroids alone), and each of the other risk factors (antibody status, lung disease, and upper respiratory tract involvement).

^‡Controlled for age, sex, race, serum creatinine level, and therapy (immunosuppressants plus corticosteroids versus corticosteroids alone).